Antibody drugs play a critical role in infectious diseases, cancer, autoimmune diseases, and inflammation. However, experimental methods for the generation of therapeutic antibodies such as using immunized mice or directed evolution remain time consuming and cannot target a specific antigen epitope. Here, we describe the application of a computational framework called OptMAVEn combined with molecular dynamics to de novo design antibodies. Our reference system is antibody 2D10, a single-chain antibody (scFv) that recognizes the dodecapeptide DVFYPYPYASGS, a peptide mimic of mannose-containing carbohydrates. Five de novo designed scFvs sharing less than 75% sequence similarity to all existing natural antibody sequences were generated using OptMAVEn and their binding to the dodecapeptide was experimentally characterized by biolayer interferometry and isothermal titration calorimetry.
INTRODUCTION
Antibodies are protective proteins used by the immune system to recognize and neutralize foreign objects through interactions with a specific part of the target, called an antigen. The high specificity and binding affinity of antibodies with antigens enables them to be used as therapeutic agents for the treatment of different diseases (Nelson et al. 2010) . Although these methods are effective, they remain time consuming, cannot target a specific epitope, and are unable to tolerate rapid changes of antigens (Sormanni et al. 2015) . Hence, advances in antibody design technology and a deeper understanding of the action of therapeutic antibodies are required for improved therapeutic antibodies (Tiller and Tessier 2015) . Computational methods for the de novo design of a fully human antibody against any specific antigen provide a route to resolve these issues (Li et al. 2014 ). This strategy, if validated, could offer a general route to therapeutic antibodies for many pathogens that have resisted traditional vaccine development, including highly antigenically-variable viruses such as HIV, influenza and Ebola virus.
To this end, we have developed a computational framework named Optimal Method for Antibody Variable region Engineering (OptMAVEn) (Li et al. 2014) for the de novo design of fully-human antibody variable domains to bind any specified antigen by assembling the six bestscored modular antibody parts (MAPs) (Pantazes and Maranas 2013) . In particular, OptMAVEn is implemented as a three-step workflow. First, for a given antigen, an ensemble of possible antigen binding conformations is generated in a modeled antibody-binding site. Second, the top scored antigen conformations and antibody models assembled by the combinations of six modular antibody parts from the MAPs database are selected. Third, random mutations are introduced to the antibody models for improved binding affinity to the antigens. This idea is inspired by the natural evolution of an antibody in vivo, in that the gene of a "germline" antibody
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This article is protected by copyright. All rights reserved variable domain is initially assembled by combining random variable (V), diversity (D), and joining (J) "germline" genes to create an antibody variable domain (Peled et al. 2008) . We have created the MAPs database (Pantazes and Maranas 2013) approximately analogous to the naturally occurring human repertoire of V, D and J genes. To improve the description of antibody structures, the MAPs database utilizes CDR3 as a structural component instead of D region (heavy chain) and partial region of V region (light chain). The primary advantage of using MAPs to de novo assemble an antibody model is that the computational overhead is manageable as the need for de novo folding calculations is bypassed by assembling structural domains. In addition, compared to traditional fragment-assembly-based approaches (Simons et al. 1997 ) for de novo protein structure prediction, OptMAVEn efficiently samples both local and non-local contacts that are inherently present in the relatively large structural fragments. To generate antibodies of high quality, molecular dynamics (MD) simulation is incorporated in the present study into the design workflow of OptMAVEn to screen against unstably bound with antigen antibodies. Although OptMAVEn is capable of generating novel computational antibody models with numerous interactions with their target epitopes, the feasibility of this protocol has not been validated by experiments until now.
Using OptMAVEn, we de novo designed single-chain antibodies (scFvs) against the dodecapeptide antigen DVFYPYPYASGS. The dodecapeptide with its Tyr-Pro-Tyr motif mimics the carbohydrate methyl α-D-mannopyranoside, which has been studied extensively since it is the recognition target of lectin concanavalin A (con A) and mAb-2D10 (Krishnan et al. 2007; Tapryal et al. 2013) . Association with the two antigens (dodecapeptide and methyl α-Dmannopyranoside) occurs at different sites for con A. Because 2D10-Fab (fragment antigenbinding) could not be crystallized, a shorter recombinant scFv-2D10 was constructed,
This article is protected by copyright. All rights reserved refolded (Tapryal et al. 2010) , and crystallized with both antigens which revealed that 2D10 has a rigid binding site that does not change upon antigen binding (Tapryal et al. 2013) . We chose dodecapeptide antigen (DVFYPYPYASGS) to test the OptMAVEn designs because it is easily synthesized, has a crystal structure bound to the scFv-2D10 (PDB ID 4H0H) (Tapryal et al. 2013) , and scFv-2D10 can be produced in Escherichia coli and activated by in vitro refolding (Tapryal et al. 2010 ).
We designed five de novo scFvs possessing distinct sequences compared to all existing natural antibody sequences that can bind with the dodecapeptide antigen using OptMAVEn.
Since the stability and activity of a protein often depend not only on its static structure but also on its dynamic properties (Mou et al. 2015) , an additional conformational sampling and stability evaluation using MD simulation was performed. The lack of sequence similarity between our designs and scFv-2D10 demonstrates that the OptMAVEn procedure broadly samples the vast sequence space and arrives at designs unbiased by the original antibody residue composition.
All five scFvs were found to be actively folded and stable in solution, and three of the scFvs showed high binding affinity to the dodecapeptide antigen (nanomolar level) while exhibiting diverse binding modes to the antigen. The results demonstrate that OptMAVEn combined with MD simulation are a promising computational approach for the de novo design of thermally and conformationally stable antibodies with high binding affinities. Figure 1 shows an overview of OptMAVEn to design the entire variable domain of an antibody targeting a specific epitope (Supplementary Text 1).
MATERIALS AND METHODS

Computational antibody generation.
Framework domains of OptMAVEn generated antibodies were aligned with existing antibodies (Supplementary Data 1) to identify allowed mutable residues.
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This article is protected by copyright. All rights reserved Experimental procedures. A series of experimental steps involving cloning methods (fasta sequences of scFvs in Supplementary Data 2 and oligonucleotide sequences used for amplifying the scFvs in Supplementary Table I) , expression, purification and refolding (Supplementary   Table II ) of scFvs, analysis of refolded scFvs by circular dichroism (CD), scFv-antigen binding affinity measurements by biolayer interferometry and isothermal titration calorimetry were described in detail in Supplementary Text 1.
RESULTS
Computational workflow with the incorporation of MD simulation. "Germline" antibody models with favorable dodecapeptide interactions were generated using OptMAVEn. Table I shows the diversity in the chosen antibody parts to recognize the manifold spatial poses of the antigen. Thereafter, all-atom MD simulations were performed to computationally assess the stability of the antibody binding site with the epitope. Additionally, for the antigens that bind stably with the antibody, the interaction at the antigen-antibody interface was refined during MD In silico affinity maturation. The assembled "germline" antibodies were expected to have only low or moderate binding affinity to the antigen. To further enhance antibody affinity we performed in silico affinity maturation to the MD-refined "germline" antibodies by randomly selecting mutations that are predicted to improve binding energy. Mutations were not limited to
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However, mutations in residues in the CDRs were allotted a 3-fold higher preference over those in the frameworks (FRs) to match expected mutational patterns observed in matured antibodies (Pantazes and Maranas 2013) . Twenty-seven "germline" antibodies refined by MD were submitted for in silico affinity maturation. The complex and IEs were used to evaluate the stability of the complex and the binding strength between the antibody and antigen, respectively.
Not surprisingly, we found that the best ten designs with the lowest IE (ranging from -550 to -360 kcal/mol) were from groups MD_SB (four) and MD_RE (six) while none were from group MD_PB (Supplementary Table IV ). This is indicative of the difficulty in introducing favorable interactions to designs with antigens partially bound.
Designs from group MD_SB were preferred as the binding location and mode was fully retained after MD simulation (Kiss et al. 2010) . We selected four designs from group MD_SB with the lowest complex and interaction energies (Table II) is between 34% and 38% (Table II) compared to their "germline" versions. This is somewhat higher than what is seen in natural antibodies (typically 5 to 20% changes in somatic mutations and average ~27 mutations per antibody variable domain (Burkovitz et al. 2014) ) but comparable to that of HIV-1-neutralizing antibodies (ranging from 15% to 44% (Corti and Lanzavecchia 
This article is protected by copyright. All rights reserved 2013)) which take several years to accumulate. Our results suggest that the mutation rate from computational affinity maturation is higher than the average mutation rate in nature but comparable to that of somatic mutations evolved in vivo. Furthermore, all five designed antibodies share less than 50% sequence similarity with the scFv-2D10 antibody ( Fig. 3 and Table III ) and less than 60% sequence similarity within the design cohort (Table III) . We also compared the sequences of our five designs with non-redundant protein sequences (77, 704, 910 sequences) using BLAST (Altschul et al. 1990 ) and the nearest sequence to the designs identified in the protein database is CAA81438.1 (accession number). This sequence has only 74% identity with the heavy chain of scFv-5 (Supplementary Table V) , which suggests that the de novo designs truly sample new antibody sequences not observed in existing antibody sequence space.
The stated five designs (scFv-1 to scFv-5) were chosen for experimental characterization.
Purification of the de novo-designed scFvs. We produced six scFvs (five de novo designed scFvs and scFv-2D10) in E. coli as inclusion bodies and refolded them to validate the binding of de novo scFvs to antigen. Each scFv was built with a heavy chain (V H ) and light chain (V L ) of the variable regions, a hexa-histidine tag at the C-terminus, and a glycine-serine flexible linker (Gly 4 Ser 1 ) 3 between the V H and V L regions (Fig. 4a) , and was amplified with the respective primers ( Fig. 4b) . Note that the His tag was 42 Å away from the antigen-peptide active binding site so it is unlikely to affect antigen binding. All the scFvs formed inclusion bodies after induction with IPTG, and the inclusion bodies were washed in Triton X-100 detergent for removal of membrane debris (Palmer and Wingfield 2004) , solubilized in 8M urea, and purified via FPLC using Ni-NTA affinity chromatography. The purified scFvs were refolded by gradually reducing the urea concentration (from 8 M to 0 M, Supplementary Table II) . To accomplish removal of urea from 2 M to 0 M, arginine hydrochloride to suppresses protein aggregation and
This article is protected by copyright. All rights reserved oxidized glutathione for the formation of disulfide bonds was added to the refolding buffer (Umetsu et al. 2003) . Yields for the six scFvs were verified by SDS-PAGE (Fig. 4c) .
Secondary structure analysis of de novo designed scFvs. To confirm correct folding of scFvs, the secondary structures of the six purified scFvs were monitored by far-UV CD spectroscopy and compared to that of other scFvs (Blanco-Toribio et al. 2014; Glaven et al. 2012; Song et al. 2014 ). The far-UV CD spectra (190-240 nm) for the six scFvs (Fig. 4d) showed the scFvs were predominantly β-sheets, as expected for typical members of the immunoglobulin family, including scFvs (Supplementary Table VI) (Blanco-Toribio et al. 2014; Glaven et al. 2012; Gregoire et al. 1996; Lee et al. 2013; Song et al. 2014 ). The scFv-2D10 (PDB ID-4H0H) crystal structure showed the presence of 4% helical and 47% beta sheet secondary structures (Tapryal et al. 2013) , whereas the CD data for the scFv-2D10 in our hands retrieved 3.4%, 5%, and 9% helical and 40%, 38%, and 27% beta sheet structures from CDSSTR, CONTIN, and GOR4, respectively (Supplementary Table 6 ). With the recognition that CD spectral data is suitable primarily for the determination of gross secondary structure changes, the crystal structure information (percentage of helical and beta sheet content) for scFv-2D10 (PDB ID-4H0H) is clearly similar to that obtained from CD data both in solution (CDSSTR and CONTIN) (Supplementary Table 6 ) as well as predicted (GOR4) for the de novo designed scFvs (scFv-1 to scFv-5). Therefore, the CD spectral data indicate that all of our scFvs were folded properly and that de novo designs did not cause significant structural distortions.
Binding of the scFvs to the dodecapeptide using biolayer interferometry. As a quantitative assessment of the scFv-antigen complex, the association constant (k a ), dissociation constant (k d ), and equilibrium dissociation constant (K D ) values were determined (Fischer et al. 2015; Lee et al. 2014; Prischi et al. 2010; Tang et al. 2014 ) by loading the refolded His 6 tag scFvs onto Ni-NTA
This article is protected by copyright. All rights reserved biosensors and titrating with the dodecapeptide antigen using the biolayer interferometry via Octet QK system. The scFvs (550 nM) showed binding to dodecapeptide antigen (1000 nM) (Fig. 5a) . Because of the high concentrations of the antigenic peptide (1000 nM), a dissociation curve (k d ) was not observed for scFv-1, 2 and 4. From the initial sensogram (Fig. 5a) , it was clear the antigen as well as antibody concentrations were non-optimal for obtaining the proper kinetic rates for each scFv tested against the antigen; hence, we optimized the antigen concentrations using a fixed scFv-2 concentration (550 nM) and varying antigen concentrations (1000, 300, 100, (Fig. 5c ). Since we controlled the antigen concentrations (the dodecapeptide antigen was synthesized and loaded the same for each scFv), the system is robust for determining the kinetic values for the different scFvs. To rule out the non-specific binding with the biolayer interferometry, we also tested our system with various negative controls: (i) all the scFvs of our present system were titrated against a non-related peptide antigen, and (ii) a non-related scFv which was recombinantly cloned, expressed, purified, and refolded similar to the current system was titrated with the dodecapeptide antigen. Neither of the two sets of negative controls showed binding which confirms the de novo designs were specific towards their dodecapeptide targets (Fig. 5d-e) . As a
This article is protected by copyright. All rights reserved positive control, we obtained a binding constant consistent with an independent lab (0.3 nM) for an unrelated DNA-binding protein. Using the optimized scFv (550 nM) and dodecapeptide antigen (30 nM) concentrations, the binding constant K D was determined for each de novo designed scFv. Significant binding was observed between de novo designed scFv-1, 2, and 4 with the antigen along with the scFv-2D10 (Fig. 5f ). The scFv-3 and scFv-5 did not exhibit any binding. Based on the K D values for all the six scFvs tested, the best proved to be scFv-2D10 (3.7 nM) followed by scFv-1 (8.9 nM), scFv-2 (14.4 nM) and scFv-4 (23.8 nM) (Table IV) .
Isothermal titration calorimetry (ITC) was performed to corroborate the biolayer interferometry binding results using the best binders from the Octet binding study, scFv-1 and scFv-2D10, which showed a positive response with biolayer interferometry. The scFv-1 along with scFv-2D10 displayed the ~1:1 binding and showed sigmoidal behavior, an indicative of exothermic binding (Supplementary Fig. 2) . Because of the high affinity of association (K D ) (~ 1 nM), different presentation of the antigen (not conjugated to BSA), and change in buffer conditions from biolayer interferometry, it is difficult to use ITC to measure the equilibrium binding constant with precision; however, the enthalpy (ΔH), the entropy (ΔS) and stoichiometry (N) of the two scFvs that showed a positive shift with biolayer interferometry are indicative of binding to dodecapeptide antigen (Supplementary Table VII) (Kubala et al. 2010 ).
Diversity of antibody binding sites in successfully designed scFvs. As all three designs scFv-1, scFv-2 and scFv-4 exhibit low nanomolar to the dodecapeptide in the binding affinity range, their respective residue compositions were assessed to identify structural determinants favorable for binding. Figure 6a and 6b show the comparison of the amino acid compositions between the "germline" and mature antibodies in scFv-1, 2 and 4. Interestingly, Asp, Glu, Gly, Lys, and Arg occur more than any other amino acid (counts  4) in mature sequences, whereas Ala, Asn, Ile,
This article is protected by copyright. All rights reserved Leu, Thr and Tyr occur less frequently (counts  4). One of the most striking results is the dramatic decrease of aromatic residues especially tyrosine, which is consistent with the trend of in vivo somatic hypermutations of natural antibodies (Clark et al. 2006) . Tyrosine, which can provide hydrogen bonding and substantial hydrophobic interaction, is frequently found in the paratope of "germline" antibodies to promote low-affinity binding to new antigens (Dalkas et al. 2014) . Another apparent trend is that charged residues are favorable in high-affinity mature sequences. Charged-residue driven interaction could provide more specific binding than aromatic binding. Meanwhile, the numbers of aliphatic and polar residues are significantly decreased.
More polar and charged residue occurrences contribute to the improvement of binding affinity and complex stability in the solvent. A comparison of mutations before and after affinity maturation demonstrates that the net overall effect is a migration from residue types that could provide nonspecific binding to new ones that generally provide specific binding.
The sequence diversity of the three scFvs alludes to the presence of diverse modes of antigen recognition. A detailed view of the modeled interactions between the three scFvs and dodecapeptide ( Fig. 6 c-f ) reveals the differences with the scFv-2D10 antibody. In the natural antibody-peptide complex, the phenyl rings of the CDR H2 residue Tyr55 and CDRH3 residue Tyr102 of the antibody form π-π stacking interactions with the phenyl rings of the antigen residues Tyr4 and Tyr6, respectively. In contrast, cation/amino-π interactions are found to be significantly more frequent in the designed scFvs. For example, the amino group of Lys113 in the H chain of scFv-1 forms cation-π interaction with the phenyl ring of the antigen residues Tyr6 and the amino group of Lys66 in the H chain of scFv-4 forms cation-π interactions with the phenyl ring of the antigen residues Tyr6. This finding is in agreement with previous studies demonstrating that cation-π interactions are an important stabilizing factor that is more
This article is protected by copyright. All rights reserved frequently found in antibody-antigen than in protein-protein interfaces (Dalkas et al. 2014 ). The analysis of the hydrogen bond pairs revealed a preference of the hydrogen bonds formed between charged residues in the designs with the antigen. For example, Glu59 in the H chain of scFv-1 forms a hydrogen bond with the hydroxyl group of the antigen Tyr8; Asp34 and Glu108 in the L chain of scFv-2 forms a hydrogen bond with the hydroxyl groups of the antigen Tyr6 and Tyr8, respectively; the CDRH3 residue Asp109 of scFv-4 forms a hydrogen bond with the main chain nitrogen of Phe3. Notably, mutations to charged residues during affinity maturation also contribute considerably to the heavy chain variable domain-light chain variable domain (V H -V L ) association, which might stabilize the two domains and maintain the relative positions of the CDRs loops, which, in turn, can affect the antigen specificity (Chailyan et al. 2011) . For example, the CDRH3 residue Lys114 (mutated from Ala) of scFv-1 form interaction with Tyr 55 of the L chain; the CDRL2 residue Arg56 (mutated from Glu) of scFv-2 interacts with Glu113 (mutated form Asn) of the heavy chain; the CDRL2 residue Arg56 (mutated from Ala) of scFv-4 interacts with Asp109 of the heavy chain.
DISCUSSION
Despite significant progress over the past few years, the success rate of computationally designed libraries of antibodies to bind difficult-to-target epitopes is still very low (Kuroda et al. 2012 ) mostly due to our limited understanding of the process of antibody affinity maturation in vivo. It is often unclear how "germline" antibodies are assembled in the first response to antigens and how the mutations selected during the affinity maturation process contribute to improving binding affinity or selectivity or stability. To overcome these challenges, we first developed an approach named OptCDR (Pantazes and Maranas 2010) that is the first formal computational workflow for optimally selecting the residue composition of the CDRs to enhance binding for a
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This article is protected by copyright. All rights reserved given antigen. OptMAVEn (Li et al. 2014) The success rate (three out of five designs, 60%) in de novo antibody design using OptMAVEn coupled MD simulations is much higher than those of de novo protein binder design against the steroid digoxigenin (2 out of 17 designs, 12%) (Tinberg et al. 2013 ) and stem region of influenza hemagglutinin (2 out of 73 designs, 3%) (Fleishman et al. 2011) . This quantitatively demonstrates the efficacy of OptMAVEn coupled MD simulations in capturing the critical structural features of antibodies key to tight binding to antigens. Due to the similarity of general structures of the antibodies, OptMAVEn mediated de novo antibody design could efficiently sample both local and non-local contacts that are inherently present in the antibody structures using relatively large structural fragments (V, D, and J modular parts) extracted from known crystal structures, which is important for the successful design. All-atom, explicit solvent MD
This article is protected by copyright. All rights reserved simulations have previously proved to be effective at discerning active from inactive computationally designed Kemp eliminases (Kiss et al. 2010; Privett et al. 2012 ) and aiding in the prediction of domain swapping of computationally designed engrailed homeodomain protein variants (Mou et al. 2015) . Inspired by their success, we carried out MD simulations for all de novo designed "germline" antibodies with the dodecapeptide prior to in silico affinity maturation and experimental validation. Success using MD underlines its importance as a routine approach for involving dynamic properties of proteins in the selection. Encouragingly, all three of our designs exhibit high binding affinity, suggesting the potential of completely bypassing the laborious and time-consuming in vitro directed evolution and directly obtaining high affinity antibodies against a specific antigen.
Comparison of "germline" and mature sequences in the three successful designs show that a large number of mutations (>35%) in both framework and CDRs regions were introduced by in silico affinity maturation protocol. Although design scFv-5 correctly folded in solution, the failure of design scFv-5 (possessing only 22% mutations during computational affinity maturation) binding to the antigen might be due to the shortage of favorable mutations incorporated. Charged residues, especially Lys, are significantly preferred in our affinity matured designs. Analysis of the modeled interactions between the three successful scFv-dodecapeptide designs show that the CDR H3 loops of all the designed scFvs involve direct interactions with the antigen and highlight that the cation-π interactions and hydrogen bonds formed between them by charged residues are critical determinants for the high binding affinity.
Furthermore, the differences with our scFv designs and the naturally-occurring antibodies suggest that computational de novo designs generate a variety of possible antibody solutions binding to the same antigen alluding to a plethora of possible binding possibilities to achieve
This article is protected by copyright. All rights reserved high affinity. OptMAVEn's epitope-specificity implies that a cocktail of antibodies, each targeting different epitopes of the antigen, may be designed simultaneously. A cocktail of therapeutic monoclonal antibodies might be more tolerant toward antigen mutations and show better efficacy than single monoclonal antibody. For example, ZMAb, a combination of multiple-neutralizing monoclonal antibodies that recognize three different areas of the Ebola envelope GP protein have been shown to be an effective strategy to improve survival of Ebolainfected patients (Qiu et al. 2012) .
In the present OptMAVEn guided antibody generation, the target epitope comprised eight contiguous amino acids. However, most B-cell epitopes (Haste Andersen et al. 2006) in nature consist of residues from different regions of the sequence and are discontinuous. The de novo antibody designs against discontinuous epitopes present additional challenges which will be tackled in future investigations using the OptMAVEn design strategy. The successful design for the linear epitope described herein, implies that the design methodology bears great promise for streamlining and greatly facilitating the development of high-affinity antibodies for a plethora antigens such as virus envelope proteins (e.g. HIV gp120 (Pantophlet and Burton 2006) ) and tumor-associated surface proteins (e.g. B-lymphocyte antigen CD20 (Czuczman 2008) ).
CONCLUSIONS
We demonstrate here the successful application of a computational framework called OptMAVEn combined with molecular dynamics to de novo design antibodies against specific antigen-peptide target using reference system i.e. scFv-2D10, a peptide mimic of mannosecontaining carbohydrates. Among the five OptMAVEn de novo designed scFvs, three scFvs show nanomolar binding affinities to the dodecapeptide. These results reveal that OptMAVEn can efficiently de novo design thermally and conformationally stable antibodies with high
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This article is protected by copyright. All rights reserved The entire complex energy. Unit in kcal/mol. c The interaction energy between the antibody and antigen using CHARMM force field. Unit in kcal/mol. d The number of mutations between the designed mature sequence and the "germline" sequence. The mutation frequency was calculated by (number of mutations)/(number of residues in scFv except for the linker). e The mutation count for scFv-2D10 is based on the germline gene assignment in IMGT. 
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